Skip to main content
Premium Trial:

Request an Annual Quote

Quidel Gets FDA Clearance for HPIV Test

NEW YORK (GenomeWeb) – Quidel has received US Food and Drug Administration 510(k) clearance for its human parainfluenza virus molecular diagnostic test, the firm said today.

The FDA cleared the Lyra Parainfluenza Assay, a real-time PCR test for the qualitative detection and identification of human parainfluenza virus infections for virus types 1, 2, or 3 viral RNA extracted from nasal swab and nasopharyngeal swab specimens. These RNA viruses are the second leading cause of hospitalizations for respiratory disease in children under five years of age in the US, according to Quidel.

The new test is part of Quidel's Lyra brand of ready-to-use PCR reagent kits designed for use on a laboratory's existing thermal cycler. Features of the kits include a short time to result, ready-to-use master mix, and refrigerated, non-frozen storage.

With the clearance of the HPIV test, Quidel now offers FDA-cleared assays for eight different respiratory disease viruses.

Earlier this week the firm said that the FDA had cleared for marketing its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus viral DNA from nasal and nasopharyngeal swabs.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.